Gevorg Yaghjyan/LinkedIn
May 20, 2026, 14:13
Gevorg Yaghjyan: Targeting Myostatin in Clinical Trials to Preserve Muscle During Weight Loss
Gevorg Yaghjyan, Project Leader at Parexel, shared a post on LinkedIn:
“Obesity drugmakers chase weight loss. Biohaven is betting on muscles.
GLP-1s deliver weight loss, but trials keep showing a catch: approximately 25-40% of that loss can be lean muscle mass.
Biohaven’s approach: target myostatin in clinical trials to preserve muscle during weight loss.
The hypothesis — better body composition, not just lower weight, drives long-term outcomes.If the data holds, the next obesity trial endpoint might not be pounds lost. It might be muscle retained.
The weight loss race is crowded. The muscle preservation lane is wide open.”
Other posts featuring Gevorg Yaghjyan on Hemostasis Today.
-
May 20, 2026, 14:19Highlighting Women With Bleeding Disorders at the European DIU Programme – EHC
-
May 20, 2026, 14:16Sebastian Szmit: New Real-World Analysis on Atrial Fibrillation in Myeloproliferative Neoplasms
-
May 20, 2026, 14:15Caitlin Raymond: Did You Know Kcentra Is Plasma-Derived?
-
May 20, 2026, 14:14Living With von Willebrand Disease? – Share Your Experience – EHC
-
May 20, 2026, 13:10Ingmar Schön: Our paper on Thrombin-Driven Regulation of Platelet Contractility Is Now Live
-
May 20, 2026, 12:45Sergio Emanuel Kaiser: Day 6 of Road to EAS Congress 2026 challenge to So Me ambassadors
-
May 20, 2026, 12:42Mohammad Alashqar: Cost-Effectiveness of Fitusiran Prophylaxis in Severe Hemophilia A Without Inhibitors
-
May 20, 2026, 12:27Atul Gupta: Patients Share Their Personal Stroke Stories to Help Raise Public Awareness
-
May 20, 2026, 12:06Nita Radhakrishnan: The 2nd Edition of the IAP-PHO Guidelines for Thalassemia Is Now Live